Navigation Links
Singapore scientist wins coveted Chen New Investigator Award 2013
Date:4/18/2013

Dr Patrick Tan from A*STAR's Genome Institute of Singapore (GIS) has received the 2013 Chen New Investigator Award from the international Human Genome Organisation (HUGO). This award is given to scientists who have made significant contributions to their respective fields of human genetic and genomic research during their early career years, normally within 15 years from receiving their highest earned degree.

In awarding the prize, the Award Review Committee which comprises an international make-up of acclaimed scientists from countries including Canada, India, Japan, Switzerland and the USA commended Dr Tan for his outstanding education background and excellent publication record. They recognized his significant contributions through his research on genomic profiles of Asian cancers. The committee also praised him on his longstanding body of work in cancer genomics, with a particular focus on gastric cancer, and commented that his momentum appeared to be on an impressive upward trajectory.

The award will be presented at the annual meeting of HUGO, which runs from 13th through 18th April 2013 at the Marina Bay Sands Singapore. In addition to the New Investigator Award, the Chen Award for Distinguished Academic Achievement in Human Genetic and Genomic Research will also be presented at the meeting.

A graduate of Harvard University and Stanford University School of Medicine, Dr Tan's research laboratory focuses on developing genomic approaches to unlock the molecular and clinical diversity of gastric cancer. Much of his work is concerned with developing methods to differentiate and group gastric cancer patients based on their molecular profiles, and identifying the genes required for cancer to develop in each of these groups so that therapeutic treatments can be tailor-made for each specific group.

Dr Tan is also currently leading POLARIS (Personalized OMIC Lattice for Advanced Research and Improving Stratification), a consortium of multiple A*STAR Research Institutes and public healthcare centres that is driving Singapore's concerted effort to venture into stratified medicine. Besides identifying new biomarkers and technology for personalized treatment, POLARIS will also embark on education, outreach and engagement efforts.

In addition to his appointment in GIS, Dr Tan is also a Professor in the Cancer and Stem Cell Biology Program at Duke-NUS Graduate Medical School, and a Senior Principal Investigator at the Cancer Science Institute of Singapore at the National University of Singapore (NUS).

Dr Tan said, "I am deeply humbled and grateful to receive the Chen Award. This honour would not have been possible without the tireless support of my research team and our many collaborators throughout Singapore. We will redouble our efforts to translate our discoveries into applications that significantly improve health outcomes for patients in Singapore and the region."

GIS Executive Director Prof Ng Huck Hui said, "GIS is truly honoured by the recognition given to Patrick for all the important work he does in Singapore. In recent years, stratified oncology and personalized medicine have become significantly important because we want to make sure that each patient receives the best and most suitable therapeutic options available. Also, with the set-up of POLARIS under Dr Tan's leadership, there will be even closer collaborations with other research entities and clinicians toward this end. We are extremely proud of his achievements."


'/>"/>

Contact: Winnie Lim
limcp2@gis.a-star.edu.sg
656-808-8013
Agency for Science, Technology and Research (A*STAR), Singapore
Source:Eurekalert

Related medicine news :

1. Regular Distributor Conference Calls Planned For Marketing Xocolate International
2. Xocai Mayalsia
3. Xocai Taiwan
4. Xocai Singapore
5. Singapore scientists identify new biomarker for cancer in bone marrow
6. One Stop Skin Care Solutions for Dermatological Conditions in Singapore
7. National Cancer Centre Singapore scientists discover p53 mutation hinders cancer treatment response
8. Singapore scientists led by A*STARs GIS identify 4 mechanisms that contribute to gastric cancers
9. EP Global Communications, Inc, EPGL Medical Begins Selling MPDD Devices, Singapore Distributor Secures First 1,000 Units Off Assembly Line
10. Singapore clinician-scientists identify new type of deadly lymphoma
11. Dissertation Help launches services for DBA consulting in Singapore
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... 19, 2017 , ... Sales Focus Inc. (SFI), a Maryland-based sales outsourcing company, ... Over the past 20 years SFI has been recognized as the world’s leader in ... clients into the US market. The new clients include: Panacea Pro, Campseekers, Contentmart, ...
(Date:1/19/2017)... ... 2017 , ... Each year, the Southeastern Society of Plastic ... of surgeons from over fifteen different countries come together to share and learn ... to breast reconstruction for breast cancer patients, teaching these surgical techniques which ...
(Date:1/18/2017)... ... January 18, 2017 , ... A recent video posting ... global discussion about the benefits of fidgeting to relieve stress and anxiety. No ... Their Think Ink Pen had just completed a successful Kickstarter campaign raising $67,000 ...
(Date:1/18/2017)... , ... January 18, 2017 , ... ... it from the number one doctor-recommended OTC antiperspirant, Certain Dri. , Excessive sweating ... untreated. , Certain Dri created this infographic to explain the seven types of ...
(Date:1/18/2017)... ... January 18, 2017 , ... ... industry’s leading journal and most-read publication among specialty pharmacists and pharmacy professionals, ... through its Strategic Alliance Partnership (SAP) program, announced Brian Haug, president of ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... and PUNE, India , January 18, ... Allied Market Research, titled, "Breast Imaging Technologies Market by Type: ... global breast imaging technologies market size was valued at $2,544 ... by 2022, growing at a CAGR of 8.4% from 2016 ... Europe together accounted for over three-fourths market ...
(Date:1/18/2017)... 2017   Regenicin, Inc. (OTC Bulletin Board: ... the development and commercialization of regenerative cell therapies to ... reported the Company,s operating results for 2016 and an ... the Company described in its recent 10-K filing with ... accomplishments. The Company,s contract laboratory completed its evaluation of ...
(Date:1/18/2017)... DAVOS , Suiza, 18 de enero de 2017 ... biofarmacéuticas líderes lanzaron Access Accelerated, una iniciativa global para ... comunicables (NCD) y atención en países de renta baja ... NCD han alcanzado un punto de crisis, particularmente en ... casi el 80 por ciento de las muertes relacionadas ...
Breaking Medicine Technology: